All In Biotech

Drug Trial Radar · NCT04537208

Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older

Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (With or Without Adjuvant) in Healthy Adults 18 Years of Age and Older

Last checked: Nov 19, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 441 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

441

Actual

Start

Sep 3, 2020

Primary completion

Nov 19, 2021

Study completion Nov 19, 2021

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
Sep 3, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objectives of the study were: * To describe the neutralizing antibody profile at Day 1, Day 22, and Day 36 of each study intervention group. * To describe the safety profile of all participants in each age group and each study intervention group up to 12 months post-last injection. The secondary objectives of the study are: * To describe binding antibody profile at Day 1, Day 22, Day 36, Day 181 (Cohort 1) or Day 202 (Cohort 2), and Day 366 (Cohort 1) or Day 387 (Cohort 2) of each study intervention group. * To describe the neutralizing antibody profile at Day 181 (Cohort 1) or Day 202 (Cohort 2) and at Day 366 (Cohort 1) and Day 387 (Cohort 2) of each study intervention group. * To describe the occurrence of virologically-confirmed coronavirus disease (COVID-19)-like illness and serologically-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. * To evaluate the correlation / association between antibody responses to SARS-CoV-2 Recombinant Protein and the risk of virologically-confirmed COVID-19-like illness and/or serologically-confirmed SARS-CoV-2 infection.

Conditions

  • COVID-19 (Healthy Volunteers)

Interventions

  • CoV2 preS dTM-AF03 (low-dose)Biological

    Pharmaceutical form: liquid; route of administration: intramuscular injection

  • CoV2 preS dTM-AF03 (high-dose)Biological

    Pharmaceutical form: liquid; route of administration: intramuscular injection

  • CoV2 preS dTM-AS03 (low-dose)Biological

    Pharmaceutical form: liquid; route of administration: intramuscular injection

  • CoV2 preS dTM-AS03 (high-dose)Biological

    Pharmaceutical form: liquid; route of administration: intramuscular injection

  • CoV2 preS dTM (high-dose) without adjuvantBiological

    Pharmaceutical form: liquid; route of administration: intramuscular injection

  • Placebo (0.9% normal saline)Biological

    Pharmaceutical form: liquid; route of administration: intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric Mean Titers (GMTs) of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 1Time frame: Day 1 (pre-vaccination)
  2. Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 22Time frame: Day 22 (post-vaccination)
  3. Geometric Mean Titers of Neutralizing Antibodies Against SARS-CoV-2 Recombinant Protein Vaccine Formulations at Day 36Time frame: Day 36 (post-vaccination)
  4. Geometric Mean Fold-rise (GMFR) of Serum Neutralization Antibody Titers at Day 22Time frame: Day 1 (pre-vaccination) and Day 22 (post-vaccination)
  5. Geometric Mean Fold-rise of Serum Neutralization Antibody Titers at Day 36Time frame: Day 1 (pre-vaccination) and Day 36 (post-vaccination)
  6. Number of Participants With >=2-fold and >=4-fold Rise in Serum Neutralization Antibody Titers at Day 22Time frame: Day 1 (pre-vaccination) and Day 22 (post-vaccination)
  7. Number of Participants With >=2-Fold and >=4-Fold Rise in Serum Neutralization Antibody Titer at Day 36Time frame: Day 1 (pre-vaccination) and Day 36 (post-vaccination)
  8. Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 22Time frame: Day 22 (post-vaccination)
  9. Percentage of Participants Achieving Seroconversion Against SARS-CoV-2 Virus Antigens at Day 36Time frame: Day 36 (post-vaccination)
  10. Number of Participants With Immediate Unsolicited Adverse Events (AEs)Time frame: Within 30 minutes post any and each vaccination (Vaccination 1 [i.e., at Day 1] and 2 [i.e., at Day 22])
  11. Number of Participants With Solicited Injection Site ReactionsTime frame: Within 7 days post any and each vaccination (Vaccination 1 [i.e., at Day 1] and 2 [i.e., at Day 22])
  12. Number of Participants With Solicited Systemic ReactionsTime frame: Within 7 days post any and each vaccination (Vaccination 1 [i.e., Day 1] and 2 [i.e., Day 22])
  13. Number of Participants With Unsolicited Adverse EventsTime frame: Within 21 days post any and each vaccination (Vaccination 1 [i.e., Day 1] and 2 [i.e., Day 22])
  14. Number of Participants With Medically Attended Adverse Events (MAAE)Time frame: From Day 1 up to 12 months post last vaccination (i.e., up to Day 366 for Cohort 1 and up to Day 387 for Cohort 2)
  15. Number of Participants With Serious Adverse Events (SAE)Time frame: From Day 1 up to 12 months post last vaccination (i.e., up to Day 366 for Cohort 1 and up to Day 387 for Cohort 2)
  16. Number of Participants With Adverse Events of Special Interest (AESIs)Time frame: From Day 1 up to 12 months post last vaccination (i.e., up to Day 366 for Cohort 1 and up to Day 387 for Cohort 2)
  17. Number of Participants With Laboratory Test Results Based on US FDA Toxicity Grading GuidanceTime frame: From Day 1 up to 8 days post last dose (i.e., up to Day 9 for Cohort 1 and up to Day 30 for Cohort 2)

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number 8400004

    Birmingham, Alabama

  • Investigational Site Number 8400012

    Rolling Hills Estates, California

  • Investigational Site Number 8400011

    Hollywood, Florida

  • Investigational Site Number 8400019

    Melbourne, Florida

  • Investigational Site Number 8400016

    Boston, Massachusetts

  • Investigational Site Number 8400002

    Omaha, Nebraska

  • Investigational Site Number 8400001

    Rochester, New York

  • Investigational Site Number 8400007

    Rochester, New York

  • Investigational Site Number 8400008

    Cleveland, Ohio

  • Investigational Site Number 8400003

    Philadelphia, Pennsylvania

  • Investigational Site Number 8400014

    Mt. Pleasant, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.